



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

App. No. : 09/237,981
Applicant : Quertermous, et al.
Filed : 01/25/1999
TC/AU : 1644
Examiner : Nolan, Patrick J.

Confirmation No. 1644

Docket No. : 213-0094US
Customer No. : 25746

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sirs and Mesdames:

Applicant desires to bring to the attention of the Examiner the following references listed on the attached Information Disclosure Statement, Form PTO 1449. A copy of each of the references is enclosed in compliance with 37 CFR § 1.97 and 1.98. Submission of this Information Disclosure Statement should not be construed as a representation that a search has been made or that no other material information as defined in 37 C.F.R. 1.56(a) exists. This submission is not intended to constitute an admission that any patent, publication or other information referred to herein is "prior art" to the invention disclosed unless specifically so designated. The right is reserved to antedate any item under 37 C.F.R. 1.131.

It is not believed that a fee is due for consideration of the present submission but if a fee is required as set forth in 37 C.F.R. 1.17 (p) for submission of an Information Disclosure Statement under 37 C.F.R. 1.97(c) please consider this a request for consideration under the appropriate rule and an authorization for the Commissioner to charge and/ or credit Deposit Account No. 50-1922 should any additional fees be required or overpayment made.

Respectfully submitted,

Marilyn M. Huston, Reg. No. 37,851
WONG CABELLO LUTSCH RUTHERFORD & BRUCCULERI, LLP
20333 SH 249, Suite 600
Houston, Texas 77070
Direct (832) 446-2421
Facsimile (832) 446-2424

CERTIFICATE OF MAILING UNDER 1.11(a)

I hereby certify that this document is being deposited with the U.S. Postal Service Express Mail Service in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on May 27, 2004.

Amber Maxfield



INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/237,981
		Filing Date	01/25/99
		First Named Inventor	Thomas Quertermous
		Art Unit	1644
		Examiner Name	Patrick J. Nolan
Sheet 1	of 1	Attorney Docket Number	213-0094US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		MILLIGAN, JOHN F., Current Concepts in Antisense Drug Design, Journal of Medicinal Chemistry, July 9, 1993, Pgs. 1923-1937, Vol. 36, No. 14, Gilead Sciences, Foster City, CA.	
		KRAMER, RANDALL H., Human Microvascular Endothelial Cells Use B1 and B3 Integrin Receptor Complexes to Attach to Laminin, The Journal of Cell Biology, September 1990, Pgs. 1233-1243, Vol. 111, The Rockefeller University Press.	
		BIANCHI, DIANA W., Detection of Fetal Cells With 47,XY,+21 Karyotype in Maternal Peripheral Blood, Human Genetics 90, June 16, 1992, Pgs. 368-370.	
		International Search Report in related PCT application PCT/US96/09456, Quertermous et al.	
		International Preliminary Examination Report in related PCT application PCT/US96/09456, Quertermous et al.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.